L&C Bio (290650) Stock Outlook 2026: MegaDerm's Tissue-Graft Moat and the China JV Option
L&C Bio (290650) 2026 outlook for US investors: MegaDerm acellular dermal matrix and breast-reconstruction reimbursement, CartiLife cartilage regeneration, the China joint-venture manufacturing and approval option, tissue-bank supply and regulatory risk, plus xenotransplant long-term optionality.